Status:
UNKNOWN
Interferon α for the Therapy of Minimal Residual Disease
Lead Sponsor:
Peking University People's Hospital
Conditions:
Leukemia
Eligibility:
All Genders
1-60 years
Phase:
NA
Brief Summary
This study aimed to evaluate the efficacy of interferon α among patients undergone unmanipulated blood and marrow transplantation following day 60 post-transplantation who were minimal residual diseas...
Detailed Description
Standard risk acute leukemia patients (except t(9;22)(q34; q11), t(15;17), inv(16)(p13q22), t(16;16)(p13; q22), or t(8;21)(q22; q22) cytogenetic abnormalities.) undergone unmanipulated blood and marro...
Eligibility Criteria
Inclusion
- Patients who had standard-risk acute myeloid leukemia(CR1 or CR2) had minimal residual disease positive after hematopoietic stem cell transplantation
Exclusion
- Patients with t(9;22)(q34; q11), t(15;17), inv(16)(p13q22), t(16;16)(p13; q22), or t(8;21)(q22; q22) cytogenetic abnormalities;active graft-versus-host disease; active infection; organ failure; exposure to donor lymphocyte infusion prior to enrollment
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT02185261
Start Date
June 1 2014
End Date
June 1 2021
Last Update
June 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China, 100044